Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (601-610 of 755) with videos related to

Pageof 76
Sort By:
The Lancet. Rheumatology|November 8, 2023
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux diseaseMichael Hughes, Yannick Allanore, Murray Baron, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
The Journal of Rheumatology|August 3, 2011
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare WorkshopClifton O Bingham, Rieke Alten, Susan J Bartlett, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Quality indicator set for systemic sclerosisDinesh Khanna, Otylia Kowal-Bielecka, Puja P Khanna, et al.
Arthritis and Rheumatism|September 2, 2006
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosusXuebing Feng, Hui Wu, Jennifer M Grossman, et al.
BMJ Open|March 8, 2018
Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort studyErin L Merz, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Journal of Scleroderma and Related Disorders|May 19, 2017
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 25, 2019
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18Elizabeth R Volkmann, Donald P Tashkin, Masataka Kuwana, et al.
Journal of Scleroderma and Related Disorders|December 21, 2018
Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definitionY A Suliman, C Bruni, S R Johnson, et al.
Annals of the Rheumatic Diseases|April 7, 2007
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst, Norman Gaylis, Vance Bray, et al.
Pageof 76

Showing results (601-610 of 755) with videos related to

Sort By:
Pageof 76
The Lancet. Rheumatology|November 8, 2023
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux diseaseMichael Hughes, Yannick Allanore, Murray Baron, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
The Journal of Rheumatology|August 3, 2011
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare WorkshopClifton O Bingham, Rieke Alten, Susan J Bartlett, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Quality indicator set for systemic sclerosisDinesh Khanna, Otylia Kowal-Bielecka, Puja P Khanna, et al.
Arthritis and Rheumatism|September 2, 2006
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosusXuebing Feng, Hui Wu, Jennifer M Grossman, et al.
BMJ Open|March 8, 2018
Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort studyErin L Merz, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Journal of Scleroderma and Related Disorders|May 19, 2017
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 25, 2019
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18Elizabeth R Volkmann, Donald P Tashkin, Masataka Kuwana, et al.
Journal of Scleroderma and Related Disorders|December 21, 2018
Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definitionY A Suliman, C Bruni, S R Johnson, et al.
Annals of the Rheumatic Diseases|April 7, 2007
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst, Norman Gaylis, Vance Bray, et al.
Pageof 76